Bempedoic Acid in Secondary Prevention

Idine Mousavi; Vijay Nambi; Layla A. Abushamat; Sadeer G. Al-Kindi; Michael D. Shapiro; Laurence Sperling; Salim S. Virani; Abdul Mannan Khan Minhas

doi:10.1016/j.ajpc.2024.100715

Bempedoic Acid in Secondary Prevention

Idine Mousavi, Vijay Nambi, Layla A. Abushamat, Sadeer G. Al-Kindi, Michael D. Shapiro, Laurence Sperling, Salim S. Virani, Abdul Mannan Khan Minhas

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

•Bempedoic acid has been shown to reduce major adverse cardiovascular outcomes in patients unable to take statins due to statin-associated side effects.•Analysis of CLEAR Outcomes trial data reveals possible differences in baseline characteristics between the primary and secondary prevention subgroups.•Further research is needed to optimize use of bempedoic acid and clarify its impact on cardiovascular outcomes in diverse patient populations.

Original language	English (US)
Article number	100715
Pages (from-to)	100715
Journal	American Journal of Preventive Cardiology
Volume	19
DOIs	https://doi.org/10.1016/j.ajpc.2024.100715
State	Published - Sep 2024

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.ajpc.2024.100715

Cite this

@article{c79d95b7886146fb917240b40865f490,

title = "Bempedoic Acid in Secondary Prevention",

abstract = "•Bempedoic acid has been shown to reduce major adverse cardiovascular outcomes in patients unable to take statins due to statin-associated side effects.•Analysis of CLEAR Outcomes trial data reveals possible differences in baseline characteristics between the primary and secondary prevention subgroups.•Further research is needed to optimize use of bempedoic acid and clarify its impact on cardiovascular outcomes in diverse patient populations.",

author = "Idine Mousavi and Vijay Nambi and Abushamat, {Layla A.} and Al-Kindi, {Sadeer G.} and Shapiro, {Michael D.} and Laurence Sperling and Virani, {Salim S.} and Minhas, {Abdul Mannan Khan}",

note = "{\textcopyright} 2024 The Author(s).",

year = "2024",

month = sep,

doi = "10.1016/j.ajpc.2024.100715",

language = "English (US)",

volume = "19",

pages = "100715",

journal = "American Journal of Preventive Cardiology",

issn = "2666-6677",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Bempedoic Acid in Secondary Prevention

AU - Mousavi, Idine

AU - Nambi, Vijay

AU - Abushamat, Layla A.

AU - Al-Kindi, Sadeer G.

AU - Shapiro, Michael D.

AU - Sperling, Laurence

AU - Virani, Salim S.

AU - Minhas, Abdul Mannan Khan

PY - 2024/9

Y1 - 2024/9

N2 - •Bempedoic acid has been shown to reduce major adverse cardiovascular outcomes in patients unable to take statins due to statin-associated side effects.•Analysis of CLEAR Outcomes trial data reveals possible differences in baseline characteristics between the primary and secondary prevention subgroups.•Further research is needed to optimize use of bempedoic acid and clarify its impact on cardiovascular outcomes in diverse patient populations.

AB - •Bempedoic acid has been shown to reduce major adverse cardiovascular outcomes in patients unable to take statins due to statin-associated side effects.•Analysis of CLEAR Outcomes trial data reveals possible differences in baseline characteristics between the primary and secondary prevention subgroups.•Further research is needed to optimize use of bempedoic acid and clarify its impact on cardiovascular outcomes in diverse patient populations.

UR - http://www.scopus.com/inward/record.url?scp=85200815144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85200815144&partnerID=8YFLogxK

U2 - 10.1016/j.ajpc.2024.100715

DO - 10.1016/j.ajpc.2024.100715

M3 - Comment/debate

C2 - 39224771

AN - SCOPUS:85200815144

SN - 2666-6677

VL - 19

SP - 100715

JO - American Journal of Preventive Cardiology

JF - American Journal of Preventive Cardiology

M1 - 100715

ER -

Bempedoic Acid in Secondary Prevention

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this